GLP-1 weight-loss drug, whose full name is Glucagon-like peptide-1 receptor agonist. Initially, GLP-1 was a hormone secreted by the gastrointestinal tract mainly used for treating diabetes, but it has also been used to suppress appetite and control weight.
Earnings Call Summary | Pfizer(PFE.US) Q1 2025 Earnings Conference
Pfizer Targets $7.7B in Operational Efficiency Savings by 2027, Highlights Strategic R&D Shifts
Viking Among Notable Gainers as Pfizer Raises Deal Prospects
Eli Lilly Set To Report Earnings As Investors Eye Weight Loss Drug Momentum
Pfizer Shares Are Trading Higher Following a Q1 EPS Beat. The Company Reaffirmed Guidance but Said It Is Trending Towards the Upper End of Its 2025 Adjusted Diluted EPS Guidance Range.
Novo Nordisk Shares Are Trading Higher After the Company Announced Wegovy Partnerships With Hims and LifeMD.